PD-1 — Drug Target

All drugs that target PD-1 — marketed and clinical-stage. Includes 14 drug classes acting on this target.

Drug classes

Programmed Death Receptor-1 Blocking Antibody [EPC] · PD-1 inhibitor · PD-1 inhibitor + chemotherapy combination · Programmed Death Ligand-1 Blocker [EPC] · Immune checkpoint inhibitor · CAR-T cell therapy · PD-1 inhibitor and chemotherapeutic agents · Immune checkpoint inhibitor + Chemotherapy · PD-1/PD-L1 inhibitor · PD-1 inhibitor + Chemotherapy · PD-1 inhibitor combination therapy · PD-1 inhibitor (combination with chemotherapy)

Marketed (17)

• Libtayo · Regeneron Pharmaceuticals · Oncology
  Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.
• Tevimbra · Beigene · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology
  Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
• Jemperli · GSK · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology
  Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.
• JEMPERLI · GLAXOSMITHKLINE · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology
  Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response.
• Cemiplimab-Rwlc · H. Lee Moffitt Cancer Center and Research Institute · PD-1 inhibitor · Oncology
  Cemiplimab-Rwlc is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• PD-1 combined with chemotherapy · Shandong Provincial Hospital · PD-1 inhibitor + chemotherapy combination · Oncology
  PD-1 inhibitor combined with chemotherapy blocks immune checkpoint PD-1 to restore anti-tumor T-cell activity while chemotherapy directly kills cancer cells.
• K8 · Michelle Abou-Jaoude · PD-1 inhibitor · Oncology
  K8 is a monoclonal antibody that targets the PD-1 receptor.
• Tislelizumab + radiotherapy · First Affiliated Hospital Xi'an Jiaotong University · PD-1 inhibitor · Oncology
  Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses, and is combined with radiotherapy to enhance local and systemic tumor control.
• Short-term Sintilimab · Shanghai Jiao Tong University School of Medicine · PD-1 inhibitor · Oncology
  Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• Vevye® · Baylor College of Medicine · PD-1 inhibitor · Oncology
  Vevye is a monoclonal antibody that targets and inhibits the PD-1 receptor.
• Tislelizumab + platinum-based chemotherapy · Fujian Cancer Hospital · PD-1 inhibitor · Oncology
  Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells.
• Unloxcyt · Checkpoint Therapeutics Inc · Programmed Death Ligand-1 Blocker [EPC] · Oncology
  Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells.
• PD-1 Monoclonal Antibody · Peking University People's Hospital · PD-1 inhibitor · Oncology
  This monoclonal antibody binds to PD-1 on T cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.
• Penpulimab kcqx · Akeso Biopharma · Oncology
  Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer.
• Loqtorzi · Coherus Biosciences Inc · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology
  Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
• "MAX-40279-01" and "Toripalimab" · Maxinovel Pty., Ltd. · PD-1 inhibitor · Oncology
  Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• Actilitio® · Centro de Atencion e Investigacion Medica · PD-1 inhibitor · Oncology
  Actilitio is a monoclonal antibody that targets the PD-1 receptor.

Phase 3 pipeline (172)

• KAI-9531 · Kailera · PD-1 inhibitor · Oncology
  KAI-9531 is a small molecule that targets the PD-1 receptor.
• Keytruda-EU · Sandoz · PD-1 inhibitor · Oncology
  Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• s.c. injection · Leti Pharma GmbH · PD-1 inhibitor · Oncology
  This drug targets the PD-1 receptor to modulate the immune response.
• HB0017 Q8W · Huabo Biopharm Co., Ltd. · PD-1 inhibitor · Oncology
  HB0017 Q8W is a monoclonal antibody targeting the PD-1 receptor.
• HLX02 · Shanghai Henlius Biotech · PD-1 inhibitor · Oncology
  HLX02 is a monoclonal antibody that binds to and blocks the PD-1 checkpoint receptor on immune cells, allowing them to recognize and attack cancer cells.
• PD-1 antibody · Sun Yat-sen University · PD-1 inhibitor · Oncology
  A PD-1 antibody blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.
• PD-1inhibitor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · PD-1 inhibitor · Oncology
  A PD-1 inhibitor blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.
• SM-1 · Sequential Medicine Ltd · PD-1 inhibitor · Oncology
  SM-1 is a small molecule that targets the PD-1 receptor.
• PAXG · Associazione Italiana per lo Studio del Pancreas · PD-1 inhibitor · Oncology
  PAXG is a drug that targets the PD-1 receptor.
• PF-06462700 · Pfizer · PD-1 inhibitor · Oncology
  PF-06462700 is a small molecule that targets the PD-1 receptor.
• TAR-200 · Janssen Research & Development, LLC · PD-1 inhibitor · Oncology
  TAR-200 is a monoclonal antibody targeting the PD-1 receptor.
• Sintilimab Combined With Docetaxel Monotherapy · Ye jinjun · PD-1 inhibitor · Oncology
  Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.
• US-Keytruda® · Bio-Thera Solutions · PD-1 inhibitor · Oncology
  US-Keytruda is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• US-sourced YERVOY® · Shanghai Henlius Biotech · PD-1 inhibitor · Oncology
  YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.
• AGS (Experimental) · Ahn-Gook Pharmaceuticals Co.,Ltd · Immune checkpoint inhibitor · Oncology
  AGS is an experimental drug that targets the PD-1/PD-L1 pathway.
• Camrelizumab and Chemotherapy · Yue He, MD · PD-1 inhibitor · Oncology
  Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.
• Continuous PD-1 inhibitor therapy · Canadian Cancer Trials Group · PD-1 inhibitor · Oncology
  Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses.
• Camrelizumab plus chemo-radiotherapy · Sun Yat-sen University · PD-1 inhibitor · Oncology
  Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing.
• Concurrent PD-1 antibody · Sun Yat-sen University · PD-1 inhibitor · Oncology
  A PD-1 antibody that blocks the PD-1 checkpoint protein on T cells, allowing the immune system to recognize and attack cancer cells.
• Intermittent PD-1 inhibitor therapy · Canadian Cancer Trials Group · PD-1 inhibitor · Oncology
  Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern.
• AD-221C · Addpharma Inc. · PD-1 inhibitor · Oncology
  AD-221C is a small molecule that targets the PD-1 receptor.
• Pembrolizumab, Sintilimab · Hunan Province Tumor Hospital · PD-1 inhibitor · Oncology
  Pembrolizumab and Sintilimab are PD-1 inhibitors that block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses.
• Systemic Therapy/Standard of Care · Memorial Sloan Kettering Cancer Center · PD-1 inhibitor · Oncology
  This drug targets the PD-1 receptor to inhibit cancer cell growth.
• HX008 + TACE · Taizhou Hanzhong biomedical co. LTD · PD-1 inhibitor · Oncology
  HX008 is a PD-1 inhibitor combined with TACE (transarterial chemoembolization) to enhance anti-tumor immunity while delivering localized chemotherapy to hepatic tumors.
• TORIPALIMAB INJECTION(JS001 ) · First Affiliated Hospital of Zhejiang University · PD-1 inhibitor · Oncology
  Toripalimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immunity.
• ATGC-110 · ATGC Co., Ltd. · PD-1 inhibitor · Oncology
  ATGC-110 is a small molecule that targets the PD-1 receptor.
• guideline-recommended SoC · Shanghai East Hospital · PD-1 inhibitor · Oncology
  This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells.
• Tislelizumab（adjuvant） · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · PD-1 inhibitor · Oncology
  Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response.
• Toripalimab injection · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · PD-1 inhibitor · Oncology
  Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• AD-221B · Addpharma Inc. · PD-1 inhibitor · Oncology
  AD-221B is a small molecule that targets the PD-1 receptor.
• Pembrolizumab SC · Merck Sharp & Dohme LLC · PD-1 inhibitor · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
• Y-3 for injection · Beijing Tiantan Hospital · PD-1 inhibitor · Oncology
  Y-3 for injection is a monoclonal antibody that targets the PD-1 receptor.
• placebo /IBI112 · Innovent Biologics (Suzhou) Co. Ltd. · PD-1 inhibitor · Oncology
  IBI112 is an anti-PD-1 monoclonal antibody.
• (D) DWC202207 · Daewoong Pharmaceutical Co. LTD. · PD-1 inhibitor · Oncology
  DWC202207 is a drug that targets the PD-1 receptor.
• Classic treatment · Sherief Abd-Elsalam · PD-1 inhibitor · Oncology
  This drug works by inhibiting the PD-1 receptor, which is involved in the immune system's response to cancer cells.
• TNM002 · Zhuhai Trinomab Pharmaceutical Co., Ltd. · PD-1 inhibitor · Oncology
  TNM002 is a monoclonal antibody targeting PD-1.
• AD-223C · Addpharma Inc. · PD-1 inhibitor · Oncology
  AD-223C is a small molecule that targets the PD-1 receptor.
• Pembrolizumab (MK-3475) · Memorial Sloan Kettering Cancer Center · PD-1 inhibitor · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
• AG2304T · Ahn-Gook Pharmaceuticals Co.,Ltd · PD-1 inhibitor · Oncology
  AG2304T is a small molecule targeting the PD-1 receptor.
• cMAB · European Organisation for Research and Treatment of Cancer - EORTC · PD-1 inhibitor · Oncology
  cMAB is a monoclonal antibody targeting the PD-1 receptor.

Phase 2 pipeline (11)

• BMS-986165 Dose A · Bristol-Myers Squibb · PD-1 inhibitor · Oncology
  BMS-986165 Dose A is an anti-PD-1 monoclonal antibody.
• FK-PC101 · Cellvax Therapeutics Inc · PD-1/PD-L1 inhibitor · Oncology
  FK-PC101 is a small molecule that targets the PD-1/PD-L1 axis.
• COR-1 · Corimmun GmbH · PD-1 inhibitor · Oncology
  COR-1 is a monoclonal antibody targeting the PD-1 receptor.
• D10NS · MemorialCare · PD-1 inhibitor · Oncology
  D10NS is a drug that targets the PD-1 receptor.
• AB103 · Atox Bio Ltd · PD-1 inhibitor · Oncology
  AB103 is a monoclonal antibody targeting the PD-1 receptor.
• EMB-01 · Shanghai EpimAb Biotherapeutics Co., Ltd. · Oncology
  EMB-01 is an investigational monoclonal antibody targeting PD-1.
• Delayed Maintenance treatment · GlaxoSmithKline · PD-1 inhibitor · Oncology
  This drug targets the PD-1 receptor to suppress cancer cell growth.
• BRY812 for injection · BioRay Pharmaceutical Co., Ltd. · PD-1 inhibitor · Oncology
  BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor.
• BMS-986368 · Celgene · anti-PD-1 monoclonal antibody · Oncology
  BMS-986368 is an anti-PD-1 monoclonal antibody.
• 2014-ALC-919-US · Veloce BioPharma LLC · PD-1 inhibitor · Oncology
  This drug targets the PD-1 receptor to modulate the immune response.
• Anti-PD1 Monoclonal Antibody · City of Hope Medical Center · PD-1 inhibitor · Oncology
  Inhibits PD-1 receptor